HomeInsightsStock Comparison

Astrazeneca Pharma India Ltd vs Jubilant Pharmova Ltd Stock Comparison

Astrazeneca Pharma India Ltd vs Jubilant Pharmova Ltd Stock Comparison

Last Updated on: May 24, 2025

Key Highlights

  • The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 7972 as of 23 May 15:30.
  • The P/E Ratio of Astrazeneca Pharma India Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Jubilant Pharmova Ltd changed from 4.4 on March 2020 to 116.5 on March 2024 . This represents a CAGR of 92.56% over 5 years.
  • The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Jubilant Pharmova Ltd changed from ₹ 3964 crore on March 2020 to ₹ 9056 crore on March 2024 . This represents a CAGR of 17.97% over 5 years.
  • The revenue of Astrazeneca Pharma India Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Jubilant Pharmova Ltd for the Mar '25 is ₹ 1940 crore as compare to the Dec '24 revenue of ₹ 1830 crore. This represent the growth of 6%.
  • The ebitda of Astrazeneca Pharma India Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Jubilant Pharmova Ltd for the Mar '25 is ₹ 353.9 crore as compare to the Dec '24 ebitda of ₹ 277.4 crore. This represent the growth of 27.58%.
  • The net profit of Astrazeneca Pharma India Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Jubilant Pharmova Ltd changed from ₹ 6 crore to ₹ 151.3 crore over 8 quarters. This represents a CAGR of 402.16% .
  • The Dividend Payout of Astrazeneca Pharma India Ltd changed from 3.46 % on March 2020 to 37.15 % on March 2024 . This represents a CAGR of 60.76% over 5 yearsThe Dividend Payout of Jubilant Pharmova Ltd changed from 24.8 % on March 2020 to 251.58 % on March 2024 . This represents a CAGR of 58.94% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Astrazeneca Pharma India Ltd

  • AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
  • The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
  • The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
  • Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Jubilant Pharmova Ltd

  • Jubilant Pharmova Limited, (Formerly known as Jubilant Life Sciences Limited), is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.
  • The Company is engaged in pharmaceuticals, contract research and development services and proprietary novel drugs.
  • The pharmaceuticals segment, through wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of Active Pharmaceutical Ingredients (APIs), Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectables and Non-Sterile Products through 6 US FDA approved manufacturing facilities in India, USA and Canada with a network of over 48 radiopharmacies in the USA. The contract research and development segment provides drug discovery and development services as well as clinical data software and service solutions.

Astrazeneca Pharma India Ltd News Hub

News

Astrazeneca Pharma India announces board meeting date

Astrazeneca Pharma India will hold a meeting of the Board of Directors of the Company on 3...

Read more

22 May 2025 16:02

News

AstraZeneca Pharma gets CDSCO nod to import and distribute TAGRISSO (Osimertinib)

The newly approved indication allows Osimertinib to be used in combination with pemetrexed...

Read more

05 Apr 2025 14:43

News

Astrazeneca Pharma gains after receiving approval from CDSO to import Durvalumab solution.

Through this approval, Durvalumab in combination with Tremelimumab is indicated for the tr...

Read more

03 Mar 2025 14:43

News

Astrazeneca Pharma gains after Q3 PAT soars to Rs 55 cr

Revenue from operations jumped 44% to Rs 440.29 crore in Q3 FY25 as compared with Rs 305.7...

Read more

12 Feb 2025 11:47

News

Astrazeneca Pharma India to hold board meeting

Astrazeneca Pharma India will hold a meeting of the Board of Directors of the Company on 1...

Read more

21 Jan 2025 10:45

News

Volumes spurt at Astrazeneca Pharma India Ltd counter

Happiest Minds Technologies Ltd, Campus Activewear Ltd, Cera Sanitaryware Ltd, ITI Ltd are...

Read more

30 Dec 2024 14:30

Jubilant Pharmova Ltd News Hub

News

Board of Jubilant Pharmova recommends final dividend

Jubilant Pharmova announced that the Board of Directors of the Company at its meeting held...

Read more

16 May 2025 14:12

News

Jubilant Pharmova jumps after reporting turnaround Q4 performance

Revenue from operations increased 9.7% YoY to Rs 1,915.80 crore in Q4 FY25. The company re...

Read more

16 May 2025 16:07

News

Jubilant Pharmova to hold board meeting

Jubilant Pharmova will hold a meeting of the Board of Directors of the Company on 16 May 2...

Read more

02 May 2025 13:52

News

Jubilant Pharmova arm gets EIR from USFDA for Maryland facility

The US Food and Drug Administration (USFDA) had classified the inspection as voluntary act...

Read more

13 Mar 2025 10:18

News

Volumes spurt at Jubilant Pharmova Ltd counter

K E C International Ltd, Indian Bank, J B Chemicals & Pharmaceuticals Ltd, Birla Corporati...

Read more

13 Mar 2025 11:00

News

Jubilant Pharmova announces acquisition of 80% stake in JASMIN

Jubilant Biosys Innovative Research Services, Singapore (JBIRSPL), a subsidiary of Jubilan...

Read more

29 Jan 2025 09:03

SWOT Analysis Of Jubilant Pharmova Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Jubilant Pharmova Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Astrazeneca Pharma India Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Astrazeneca Pharma India Ltd and Jubilant Pharmova Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Jubilant Pharmova Ltd?

Market cap of Astrazeneca Pharma India Ltd is 19,930 Cr while Market cap of Jubilant Pharmova Ltd is 17,102 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Jubilant Pharmova Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Jubilant Pharmova Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Jubilant Pharmova Ltd?

As of May 24, 2025, the Astrazeneca Pharma India Ltd stock price is INR ₹7972.0. On the other hand, Jubilant Pharmova Ltd stock price is INR ₹1073.6.

How do dividend payouts of Astrazeneca Pharma India Ltd and Jubilant Pharmova Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Jubilant Pharmova Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions